Circassia Pharma

57 articles with Circassia Pharma

• Circassia Limited Interim Management Statement

  11/11/2014

• Circassia Limited Raises $332 Million In IPO Debut, Largest Biotech IPO Since 1995

  3/14/2014

• Circassia Limited Seeks $285 Million In One Of Europe's Biggest Biotech IPOs

  2/6/2014

• Circassia Limited Appoints Paul R Edick to Its Board of Directors

  10/17/2013

• Circassia Limited's Grass Allergy Treatment Achieves Significant Symptom Reduction During Hay Fever Season

  10/1/2013

• Circassia Limited Appoints Dr. Francesco Granata as Chairman

  9/25/2013

• Circassia Limited's Short-Course House Dust Mite Allergy Treatment Achieves Significant Long-Term Symptom Reduction

  9/12/2013

• Circassia Limited's Cat Allergy Treatment Shows Sustained Symptom Improvement

  2/25/2013

• Circassia Limited Appoints Dr Jean-Jacques Garaud to Its Board of Directors

  12/6/2012

• Circassia Limited Initiates Pivotal Phase 3 ToleroMune® Trial in Cat Allergen-Induced Rhinoconjunctivitis

  10/4/2012

• Circassia Limited Announces Publication of ToleroMune® Cat Allergy Treatment Clinical Results in Journal of Allergy and Clinical Immunology

  9/27/2012

• Circassia Limited Appoints Dr Brett Haumann as Chief Medical Officer

  9/11/2012

• National Institutes of Health (NIH) Awards $6.4 Million to Professor Mark Larche to Investigate Mechanisms of Allergy Tolerance Generated by Circassia Limited's ToleroMune® Treatment

  6/7/2012

• Circassia Limited's Ragweed Allergy Therapy Achieves Positive Phase II Clinical Results

  3/8/2012

• Circassia Limited's Hay Fever Treatment Improves Patients’ Allergy Symptoms in Phase II Clinical Trial

  9/27/2011

• Circassia Limited's Hay Fever Treatment Improves Patients' Allergy Symptoms in Phase II Clinical Trial

  9/27/2011

• Circassia Limited's Rapid Four-Dose ToleroMune® Treatment Maintains Significant Reduction in Allergy Symptoms During 12-Month Follow-up

  6/13/2011

• Circassia Limited's Rapid Four-Dose ToleroMune(R) Treatment Maintains Significant Reduction in Allergy Symptoms During 12-Month Follow-up

  6/13/2011

• Circassia Limited Completes $98 Million Fundraising for Final-Stage Development of Lead Allergy Products

  4/19/2011

• Circassia Limited Acquires Worldwide Rights to Novel Psoriasis and Atopic Dermatitis Treatment from Airmid Inc.

  2/9/2011